Am­gen sweeps last BC­MA BiTE stand­ing out of pipeline

Ex­act­ly a year af­ter re­sum­ing dos­ing on a bis­pe­cif­ic that hits BC­MA, Am­gen is scrap­ping the drug al­to­geth­er for “strate­gic rea­sons.”

The move — along with a sep­a­rate de­ci­sion to de­pri­or­i­tize aca­p­atam­ab in fa­vor of an­oth­er PS­MA-tar­get­ing drug, AMG 340, for the treat­ment of metasta­t­ic cas­trate-re­sis­tant prostate can­cer — marks an­oth­er round of tri­al and er­ror as Am­gen fig­ures out the best con­fig­u­ra­tions and us­es of its half-life ex­tend­ed bis­pe­cif­ic T cell en­gagers (BiTEs).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.